Core Viewpoint - JD Health (06618) is expected to outperform market expectations in the second half of 2025, driven by a surge in flu cases leading to increased demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's stock rose over 6%, reaching HKD 62 with a trading volume of HKD 411 million [1] - Nomura forecasts that JD Health's revenue for Q4 2025 will reach RMB 20 billion, representing a year-on-year growth of 22% [1] - The growth in Q4 2025 is attributed to sales increases in pharmaceuticals (30%), nutritional products (20%), and medical devices (10%) [1] Group 2: Market Trends - The increase in flu cases in Q4 2025 is expected to significantly boost pharmaceutical sales, contributing a high single-digit percentage to total sales [1] - The sales of medical devices, such as home oxygen concentrators, are also anticipated to rise due to the flu season [1] - Nutritional brands will continue effective marketing campaigns in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - CICC noted strong revenue performance for JD Health in 2025, with quarterly growth rates around 25% year-on-year for Q1 to Q3 [1] - The company has signed strategic cooperation agreements with pharmaceutical companies like Eli Lilly, Innovent Biologics, and Bayer China, enhancing its unique business model of launching new drugs online [1] - The ongoing trend of increasing original drug volumes is expected to support strong revenue performance in Q4 2025 [1]

Core Viewpoint - JD Health is expected to outperform market expectations in the second half of 2025, primarily due to a surge in flu cases driving up demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's revenue for Q4 2025 is projected to reach 20 billion RMB, representing a year-on-year growth of 22%, driven by sales growth in pharmaceuticals, nutritional products, and medical devices at 30%, 20%, and 10% respectively [1] - The company has shown strong revenue performance throughout 2025, with each quarter from Q1 to Q3 achieving approximately 25% year-on-year growth [1] - The overall revenue growth for JD Health in 2025 is anticipated to be close to 25% year-on-year [1] Group 2: Market Dynamics - The increase in flu cases in Q4 2025 is expected to significantly contribute to pharmaceutical sales, accounting for a high single-digit percentage of total pharmaceutical revenue [1] - The sales of medical devices, such as home oxygen concentrators, are also expected to rise due to the flu outbreak [1] - JD Health's nutritional brands will continue to implement effective marketing strategies in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - JD Health has signed strategic cooperation agreements with pharmaceutical companies such as Eli Lilly, Innovent Biologics, and Bayer China, enhancing its business model of launching new drugs online [1]

Core Viewpoint - JD Health's stock price has increased by 5.58%, reaching HKD 61.45, with a trading volume of HKD 230 million, driven by positive forecasts for its performance in the second half of 2025, particularly in Q4 due to a surge in flu cases increasing demand for medications [1][2] Group 1: Performance Forecasts - Nomura predicts that JD Health's Q4 2025 revenue will reach RMB 20 billion, representing a year-on-year growth of 22%, supported by sales growth of 30%, 20%, and 10% in pharmaceuticals, nutritional products, and medical devices respectively [1][2] - The report highlights that flu-related medications will account for a significant percentage of pharmaceutical sales, alongside increased sales of home medical devices like oxygen concentrators [1][2] Group 2: Revenue and Profit Adjustments - CICC has raised its revenue forecasts for JD Health for 2025 and 2026 by 2% to RMB 72.5 billion and RMB 81.7 billion respectively, considering the ongoing demand for original research products and strong flu-related product demand [1][2] - The firm has also adjusted its non-IFRS net profit estimates for 2025 and 2026 upwards by 4% and 1% to RMB 6.5 billion and RMB 6.4 billion respectively, and introduced a revenue forecast for 2027 of RMB 91.2 billion with a non-IFRS net profit forecast of RMB 6.8 billion [1][2] Group 3: Target Price and Rating - CICC maintains a target price of HKD 71.4 for JD Health, indicating a 23% upside potential, while sustaining an "outperform" rating despite recent fluctuations in the sector [1][2]